MK-2461 / Merck (MSD) - LARVOL DELTA

Targeting the c-MET/HGF signaling pathway in pancreatic ductal adenocarcinoma. (PubMed, Curr Pharm Des) - "It is likely that within the next few years, HGF/Met inhibitors will become a crucial component for cancer management. In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV-299), Rilotumumab (AMG 102), NK4 in pancreatic cancer."

Journal